Kcentra Resources Here you will find important information and resource downloads for Kcentra.

Urgent Warfarin Reversal Presentation by Dr. Blinder

Video Presentation:
Kcentra Educational Slide Deck

Learn more about the clinical data, dosing, reconstitution, administration for Kcentra.

Kcentra Educational Slide Deck

Video Presentation:
Kcentra for Urgent Warfarin Reversal

Kcentra Method of Action Video

Kcentra Mechanism of Action Video

Reconsitution Guide

Kcentra Reconstitution Guide

Learn how to reconstitute Kcentra using the Mix2Vial® Transfer Set.

Formulary Kit

Kcentra Formulary Kit

Important product information for Kcentra, including disease state, in-depth review of clinical study results and safety information.

To ensure complete functionality of the interactive Formulary Kit, please save the PDF to your desktop, then open in Adobe® Acrobat®.

Reimbursement Guide

Kcentra Reimbursement Guide

Important payment and coding information for reimbursement of Kcentra in the inpatient and outpatient hospital setting.

Reimbursement Quick Reference Guide

Kcentra Reimbursement Quick-Reference Card

Summary card with payment and coding information for reimbursement of Kcentra in the inpatient and outpatient hospital setting.

Pharmacy Detail Sheet

Kcentra Pharmacy Detail Sheet

Brief reference guide containing packaging, storage, and ordering information.

Kcentra Prescribing Information

Kcentra Prescribing Information

Full prescribing information for Kcentra, including boxed warning.

Warfarin Revresal Video

Warfarin Reversal in the Emergency Department Video

View the video "Key Considerations for Warfarin Reversal," a discussion about the anticoagulant drug warfarin.

Mix2Vial Video

Kcentra Reconstitution Instructional Video

Learn about the reconstitution of Kcentra using the Mix2Vial® Transfer Set.

Kcentra CPOE Tool

Kcentra Computerized Physician Order Entry (CPOE) Tool

A step-by-step guide to promote the safe and appropriate use of Kcentra for patients that includes a dosing calculator, patient selection guide, prescribing information, and more.

Do you want to incorporate this educational tool into your IT system?

Home Resources Resource Downloads

Important Safety Information

Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. Kcentra is for intravenous use only.


Patients being treated with Vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with history of such events. Resumption of anticoagulation therapy should be carefully considered once the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving Kcentra, and inform them of signs and symptoms of thromboembolic events. Kcentra was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Kcentra might not be suitable for patients with thromboembolic events in the prior 3 months.

Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Kcentra is also contraindicated in patients with disseminated intravascular coagulation. Because Kcentra contains heparin, it is contraindicated in patients with heparin-induced thrombocytopenia (HIT).

Hypersensitivity reactions to Kcentra may occur. If patient experiences severe allergic or anaphylactic type reactions, discontinue administration and institute appropriate treatment.

In clinical trials, the most frequent (≥2.8%) adverse reactions observed in subjects receiving Kcentra were headache, nausea/vomiting, hypotension, and anemia. The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.

Kcentra is made from human blood and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see full prescribing information for Kcentra.

CSL Behring
Kcentra is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.
Kcentra® and Beriplex® are registered trademarks of CSL Behring GmbH.
Biotherapies for Life® is a registered trademark of CSL Behring LLC
All other products mentioned are trademarks or registered trademarks of their respective companies.
© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
KCT15-03-0011a 03/2016